NCT04632316 - A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Cyclophosphamide-Fludarabine (Cy/Flu)

Lymphodepleting conditioning regimen

DRUG

oNKord®

Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells

Trial Locations (10)

RECRUITING

University Hospital Ghent, Ghent

RECRUITING

University Hospital Leuven, Leuven

NOT_YET_RECRUITING

Institut Gustave Roussy, Villejuif

RECRUITING

University Hospital Carl Gustav Carus Dresden, Dresden

RECRUITING

University Medical Center Hamburg-Eppendorf, Hamburg

RECRUITING

Hannover Medical School, Hanover

RECRUITING

University Hospital Mainz, Mainz

RECRUITING

Amsterdam UMC, Amsterdam

RECRUITING

University Hospital Basel, Basel

RECRUITING

University Hospital Zürich, Zurich